elotuzumab,venetoclax,pomalidomide,selinexor,belantamab mafodotin,lenalidomide
roche,merck,karyopharm,bms,abbvie,gsk,lightchain biosciences
['venetoclax', 'mmsm', ' clad ', 'lenalidomide', 'pomalidomide', 'elotuzumab', 'belantamab', 'selinexor', 'light chain']
#ash22 #mmsm by kevin reyes on clinical outcomes/salvage therapies in pts with r/r mm after progression on bcma-car-t overall responses were low responses to ttt that pts were resistant to was reported. some pts were re-treated with car-t (2nd) with short lived responses 
Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities